Calmodulin abolishes the changes in Ca2+ binding and transport by heart sarcolemmal membranes of spontaneously

Life Sciences
|June 24, 1985
PubMed

Insights

Calmodulin influences calcium handling in rat heart membranes. It enhances calcium binding and transport at physiological levels, normalizing differences between hypertensive and normotensive rats.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Biochemistry

Background:

  • Spontaneously hypertensive rats (SHR) exhibit altered cardiac sarcolemmal Ca2+ transport and binding compared to normotensive WKY rats.
  • Calmodulin's role in regulating these Ca2+ handling processes at physiological intracellular calcium concentrations is not fully understood.

Purpose of the Study:

  • To investigate the effects of calmodulin on Ca2+ binding and ATP-dependent Ca2+ transport in heart sarcolemmal membranes from SHR and WKY rats.
  • To determine if calmodulin can modulate the observed differences in Ca2+ handling between SHR and WKY rats.

Main Methods:

  • Isolation of heart sarcolemmal membranes from spontaneously hypertensive rats (SHR) and normotensive WKY rats.
  • Measurement of Ca2+ binding and ATP-dependent Ca2+ accumulation by sarcolemmal membranes at varying free calcium concentrations (2.10(-8)M and 4.10(-7)M) in the presence and absence of calmodulin.

Main Results:

  • At 2.10(-8)M free calcium, calmodulin did not significantly alter Ca2+ binding or ATP-dependent accumulation in either rat strain.
  • At 4.10(-7)M free calcium, calmodulin enhanced Ca2+ binding to SHR membranes and ATP-dependent Ca2+ transport in both SHR and WKY membranes.
  • Calmodulin presence suppressed the differences in Ca2+ binding and ATP-dependent accumulation between SHR and WKY membranes at 4.10(-7)M free calcium.

Conclusions:

  • Calmodulin modulates Ca2+ handling in cardiac sarcolemmal membranes, particularly at higher physiological calcium concentrations.
  • Altered calmodulin content or function may contribute to the abnormal Ca2+ handling observed in the cardiac plasma membranes of SHR.

Related Concept Videos

Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Smooth Muscle Contraction01:25

Smooth Muscle Contraction

Smooth muscle contraction is a complex process vital for various bodily functions, from maintaining blood vessel tension to facilitating the movement of food through the digestive tract. Unlike striated muscles, smooth muscle contraction begins more slowly and lasts longer.
The onset of contraction is triggered by an increase in calcium ions within the sarcoplasm, similar to the process in striated muscle. However, smooth muscles have a relatively smaller reservoir of the sarcoplasmic...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...